AlveoliX is a Swiss biotech company specialized in advanced human-relevant in vitro models, especially on organs on chip. Its AXBarrier-on-Chip technology enables the modelling of all tissue barriers, including associated mechanical forces, such as breathing or peristaltic motion. This technology supports a wide range of applications, including drug safety and efficacy testing, inhalation toxicology, and fundamental research. The AXBarrier on Chip system and its modular add ons can be seamlessly integrated into your laboratory workflow or accessed through AlveoliX’s CRO services, offering flexible solutions tailored to your research needs.
BiomimX is a pioneer in Organ-on-Chip technology, developing next-generation, clinically relevant in vitro models for pharmaceutical drug discovery and testing. BiomimX’s proprietary platform combine microfluidics, 3D cell culture, live human cells and controlled mechanical stimulation to create “Beating Organs-on-Chip” that mimic human physiology and pathology with high precision and predictability. These advanced platforms have been designed and validated to support drug discovery, safety and toxicology assessment, and efficacy testing across multiple therapeutic areas, including cardiac, musculoskeletal and fibrotic disorders, as well as gastrointestinal and lung barriers. As industry moves toward more human-relevant, non-animal models to improve predictivity and reduce development risk, BiomimX is positioned at the forefront of this transformation, bridging engineering, biology, and translational science to accelerate safer and more effective therapies to patients.
chiron's rapid advances in microfluidics technologies enables pharmaceutical and biotech innovators to derive actionable clinical insights before conducting preclinical testing or clinical trials. Our leading technologies, Re-plate™ and μMass™, enable applications for arthritis (osteoarthritis, rheumatoid arthritis) and oncology, respectively. With these platforms, chiron uses primary, human cells to deliver predictive, human-relevant data. Re-plate recreates human-like movement in-vitro to better recapitulate the healthy and diseased states of tissue within the synovial joint, as well as other organ systems in the body. μMass is the go-to solution for the robust creation and culturing of 3D solid-tumour aggregates, in a high-throughput platform, for use in oncology potency-assay applications. Both platforms are therapeutic-modality agnostic with additional applications in other disease areas.
Dynamic42 GmbH provides immunocompetent, physiological organ-on-chip models combining ISO-certified, medical-grade standards with ease of use for scientists. As a spin-off from the University Hospital Jena in Germany, the company has developed a strong background in disease and infection modeling. Dynamic42 offers contract research for preclinical drug evaluation in human models of the vasculature, liver, intestine, lung and cancer as well as customized model development. The company further is producer of the DynamicOrgan® System the open organ-on-chip platform, provides a variety of medical-grade, low drug adsorption biochips and hands-on as well as online training courses within their Dynamic42 Academy.
InSphero is the only 3D in vitro model company with the platform and expertise to modernize drug discovery in a way that empowers researchers to reach their full potential. Our innovative spheroid and organoid based models allow for more effective, safe therapies to reach the clinic through truly superior robustness, reliability, reproducibility, and scalability. InSphero’s goal is to inspire the next generation of breakthrough therapies through customer centricity, commitment to innovation, and the model of excellence.
MIMETAS (Leiden, The Netherlands) is a global leader in human-relevant disease models for drug discovery and development. Based on its proprietary OrganoPlate® platform, MIMETAS has developed a broad spectrum of disease assays with unrivalled physiological comprehensiveness. The company deploys its disease models in partnerships with the global top-50 pharmaceutical industry to find and develop first-in-class targets and compounds. MIMETAS was founded in 2013 in Leiden, the Netherlands, and has grown into a multinational company with operations in Europe, Asia, and the USA. To learn more about MIMETAS's disease modeling capabilities, its OrganoPlate®, and OrganoReady® platforms, please visit our website.
NETRI is an Techbio industrial start-up whose mission is to improve human health through the discriminating power of the nervous system. The company offers a Neuron-as-a-sensor suite (NaaS) to gain insights into the safety and efficacy of clinical or chemical compounds. NETRI focuses on pain quantification and pursues an exploratory pipeline in oncology-related adverse events, dermo-cosmetics, neurological disorders and neurotoxicity. Leveraging the natural capacity of neurons to encode biological interactions into electrical impulses, the NaaS suite features the world-first compartmentalized electrophysiology platform in standard 96-well plate format - NeuroFluidics™ MEA - which acts as a data generation hub for its digital signature libraries of tested and reference compounds. To enable the prediction of clinical outcomes, the proprietary suite includes calibrated neuronal cells, Organ-on-chip hardware, AI-trained software, digital libraries and methods.
React4Life is an Italian biotech company transforming the preclinical research landscape by successfully addressing challenges for hundreds of clients worldwide. At the heart of React4Life lies our revolutionary MIVO® technology, backed by over two decades of dedicated academic research. We are pioneers in the development of MIVO®-based organ-on-chip systems, representing a breakthrough in microphysiological technology for faithfully recapitulating human biology in the lab. MIVO® human on chip platform overcomes the limits of traditional in vitro assays and animal models. It improves the reliability and predictivity of several applications in the fields of drug testing, personalized medicine, immuno-oncology, dermocosmetics, and nutraceuticals. At React4life, Italian creativity transforms biotech challenges into customized, cutting-edge solutions. Our worldwide clients' feedback fuels our commitment to meeting their evolving needs.
TissUse is a Berlin, Germany-based, biotechnology company, which has developed a unique “Multi-Organ-Chip” platform that provides unparalleled preclinical insight on a systemic level using human tissues. This enabling technology platform consists of a miniaturized construct that closely simulates the activity of multiple human organs in their true physiological context. TissUse’s Multi-Organ-Chips provide a new approach to predict, for example, toxicity, ADME profiles and efficacy in vitro, reducing and replacing laboratory animal testing and streamlining human clinical trials. TissUse’s Multi-Organ-Chips have been utilized in a large variety of applications including drug development, cosmetics, food and nutrition and consumer products since 2012.
